ESLAW and ESLA Related Headlines
Go Back- Estrella Immunopharma reports positive phase 1 data for cancer therapy
- Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
- Estrella Immunopharma closes $8 million financing round
- Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
ESLAW and ESLA Related Press Releases
Go Back- Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
- Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
